Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | CTX130 |
Synonyms | |
Therapy Description |
CTX130 are allogeneic T lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting CD70, which recognize and bind to CD70-expressing tumor cells, potentially resulting in antitumor activity (Cancer Res 2020;80 (16 Suppl):Abstract nr 6595). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CTX130 | CTX 130|CTX-130 | CTX130 are allogeneic T lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting CD70, which recognize and bind to CD70-expressing tumor cells, potentially resulting in antitumor activity (Cancer Res 2020;80 (16 Suppl):Abstract nr 6595). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04438083 | Phase I | CTX130 | A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory Renal Cell Carcinoma | Active, not recruiting | USA | NLD | CAN | AUS | 0 |
NCT04502446 | Phase I | CTX130 | A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory T or B Cell Malignancies | Active, not recruiting | USA | CAN | AUS | 0 |